Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, IBM, and FATE and Encourages Investors to Contact the Firm
03 févr. 2023 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
DEADLINE ALERT for FATE, SHC, ARBK, and EYE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
03 févr. 2023 14h00 HE
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Feb. 03, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FATE, and Sotera and Encourages Investors to Contact the Firm
29 janv. 2023 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 29, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
DEADLINE ALERT for YMAB, FATE, and SHC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
27 janv. 2023 14h33 HE
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Jan. 27, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Super Micro, and Fate and Encourages Investors to Contact the Firm
18 janv. 2023 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Phathom Pharmaceuticals,...
Fate Therapeutics Shareholder Investigation: Submit Your Losses to Johnson Fistel
06 janv. 2023 09h35 HE
|
Johnson Fistel, LLP
SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Fate Therapeutics, Inc. (NASDAQ: FATE) (“Fate” or the “Company), any of its...
Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives
05 janv. 2023 17h00 HE
|
Fate Therapeutics, Inc.
Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents & Receivables; 3-year Operational Runway Provided through Pipeline Prioritization and Expense Reduction Advancing...
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
13 déc. 2022 08h00 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
10 déc. 2022 14h46 HE
|
Fate Therapeutics, Inc.
Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as Monotherapy and in Combination with Daratumumab Preclinical Data...
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
10 déc. 2022 10h00 HE
|
Fate Therapeutics, Inc.
FT819 Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Engineered Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Interim Phase 1 Dose-escalation Data...